Cargando…

Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects

The number of biologicals for the therapy of immunologically mediated diseases is constantly growing. In contrast to other agents that were previously introduced in rheumatologic or dermatologic diseases and only later adopted for the treatment of inflammatory bowel diseases (IBDs), the field of IBD...

Descripción completa

Detalles Bibliográficos
Autores principales: Zundler, Sebastian, Becker, Emily, Weidinger, Carl, Siegmund, Britta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532375/
https://www.ncbi.nlm.nih.gov/pubmed/28804488
http://dx.doi.org/10.3389/fimmu.2017.00891
_version_ 1783253446268289024
author Zundler, Sebastian
Becker, Emily
Weidinger, Carl
Siegmund, Britta
author_facet Zundler, Sebastian
Becker, Emily
Weidinger, Carl
Siegmund, Britta
author_sort Zundler, Sebastian
collection PubMed
description The number of biologicals for the therapy of immunologically mediated diseases is constantly growing. In contrast to other agents that were previously introduced in rheumatologic or dermatologic diseases and only later adopted for the treatment of inflammatory bowel diseases (IBDs), the field of IBD was ground breaking for the concept of anti-adhesion blockade. Anti-adhesion antibodies selectively target integrins controlling cell homing to the intestine, which leads to reduction of inflammatory infiltration to the gut in chronic intestinal inflammation. Currently, the anti-α4β7-antibody vedolizumab is successfully used for both Crohn’s disease and ulcerative colitis worldwide. In this mini-review, we will summarize the fundamental basis of intestinal T cell homing and explain the molecular groundwork underlying current and potential future anti-adhesion therapies. Finally, we will comment on noteworthy clinical aspects of anti-adhesion therapy and give an outlook to the future of anti-integrin antibodies and inhibitors.
format Online
Article
Text
id pubmed-5532375
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-55323752017-08-11 Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects Zundler, Sebastian Becker, Emily Weidinger, Carl Siegmund, Britta Front Immunol Immunology The number of biologicals for the therapy of immunologically mediated diseases is constantly growing. In contrast to other agents that were previously introduced in rheumatologic or dermatologic diseases and only later adopted for the treatment of inflammatory bowel diseases (IBDs), the field of IBD was ground breaking for the concept of anti-adhesion blockade. Anti-adhesion antibodies selectively target integrins controlling cell homing to the intestine, which leads to reduction of inflammatory infiltration to the gut in chronic intestinal inflammation. Currently, the anti-α4β7-antibody vedolizumab is successfully used for both Crohn’s disease and ulcerative colitis worldwide. In this mini-review, we will summarize the fundamental basis of intestinal T cell homing and explain the molecular groundwork underlying current and potential future anti-adhesion therapies. Finally, we will comment on noteworthy clinical aspects of anti-adhesion therapy and give an outlook to the future of anti-integrin antibodies and inhibitors. Frontiers Media S.A. 2017-07-28 /pmc/articles/PMC5532375/ /pubmed/28804488 http://dx.doi.org/10.3389/fimmu.2017.00891 Text en Copyright © 2017 Zundler, Becker, Weidinger and Siegmund. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zundler, Sebastian
Becker, Emily
Weidinger, Carl
Siegmund, Britta
Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects
title Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects
title_full Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects
title_fullStr Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects
title_full_unstemmed Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects
title_short Anti-Adhesion Therapies in Inflammatory Bowel Disease—Molecular and Clinical Aspects
title_sort anti-adhesion therapies in inflammatory bowel disease—molecular and clinical aspects
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532375/
https://www.ncbi.nlm.nih.gov/pubmed/28804488
http://dx.doi.org/10.3389/fimmu.2017.00891
work_keys_str_mv AT zundlersebastian antiadhesiontherapiesininflammatoryboweldiseasemolecularandclinicalaspects
AT beckeremily antiadhesiontherapiesininflammatoryboweldiseasemolecularandclinicalaspects
AT weidingercarl antiadhesiontherapiesininflammatoryboweldiseasemolecularandclinicalaspects
AT siegmundbritta antiadhesiontherapiesininflammatoryboweldiseasemolecularandclinicalaspects